Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
latest_posts
- 1
Relive NASA's historic Artemis 2 launch to the moon in these stunning photos - 2Outer space conditions hamper sperm's ability to navigate toward an egg
- 3Vaccine makers raise concerns over US panel's shift away from hepatitis B shots for newborns
- 4Extravagance SUVs for Seniors: Solace, Innovation, and Security
- 58 Fundamental Stages: Novice's Manual for Secure Your Android with a VPN
- Top 20 Compelling Business Books for Progress
- Vote in favor of the handheld vacuum that you love for its strong attractions!
- Finding the Universe of Computer generated Reality: Individual Encounters
- 10 Hints for an Effective New employee screening
- Vote In favor of Your #1 Compelling Female Producer
- Surging measles cases are 'fire alarm' warning that other diseases could be next
- How did birds survive while dinosaurs went extinct?
- November Lease Deals for the 2025 Kia EV6 are Too Good to Pass Up
- Mars spacecraft images pinpoint comet 3I/ATLAS's path with 10x higher accuracy. This could help us protect Earth someday
